LENSAR, Inc. LNSR Q2 2026 earnings

“In all metrics we delivered a significant second quarter, highlighted by 18% total revenue growth and 20% recurring revenue growth over the second quarter of 2025, and our strongest Adjusted EBITDA performance to date along with positive Net Income. These results reflect the continued strength of our business model, increasing utilization across our installed base, and sustained demand for the ALLY System. Importantly, procedure revenue grew 23% over the second quarter last year as surgeons continued to increase the number of procedures performed using ALLY, reinforcing our belief in the solid health of our underlying business in realizing the long-term potential of our recurring revenue model. The growth we achieved during the second quarter gives us continued confidence in the trajectory of the business. Our increasing installed base, expanding recurring revenue and healthy backlog of pending installations exiting the second quarter position us well as we continue executing on our commercial strategy, LENSAR maintains a sharp focus on driving long-term value for our shareholders, as well as our surgeon partners and the patients they serve.”